In a landmark achievement for its pioneering spirulina-based drug development platform, Lumen announced today top-line results from the sentinel cohort of its RePreve Clinical Trial evaluating LMN-201 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback